In AML models, including venetoclax/HMA-refractory contexts, these agents re-prime mitochondrial apoptosis by downregulating MCL-1 translation and repair-linked survival programs, showing synergy with HMA and BH3 mimetics like venetoclax. The gene discussed is MCL1; the disease is acute myeloid leukemia.